03/09/2026
What’s next for CAR T-cell therapy?🤔
A new Xpeer course explores critical 2025 developments in next-generation CAR T-cell platforms for high-risk and relapsed/refractory large B-cell lymphoma.
Learn about rapid manufacturing, dual-targeting and allogeneic approaches, while reviewing emerging clinical trial data and considerations around therapy sequencing and patient access.
Register for free and start learning on Xpeer: https://eu1.hubs.ly/H0y0nGP0